Disclosures for "Hemicrania continua successfully treated long-term with botulinum toxin type A: a case report"
-
Dr. Traore has nothing to disclose.
-
Dr. Restrepo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai. Dr. Restrepo has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lilly USA. Dr. Restrepo has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Kelvi/Hypothermia Devices, Inc.. Dr. Restrepo has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for SAGE Journals, The Neurohospitalist. Dr. Restrepo has stock in Hypothermia Devices, Inc. (dba Kelvi). Dr. Restrepo has stock in Eli Lilly. Dr. Restrepo has received intellectual property interests from a discovery or technology relating to health care.